The 5-HT3 Receptor Antagonist Aloxi Launched in Japan

27-Apr-2010 - Switzerland

Helsinn Healthcare SA and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announced the launch of Aloxi(R) injection. Aloxi was developed in Japan by Taiho in close cooperation with Helsinn, based on the license agreement between Taiho and Helsinn of January 2004, and its marketing approval was obtained on20 January 2010.

Chemotherapy-induced nausea and vomiting can be classified into acute nausea and vomiting which appears within 24 hours after chemotherapy administration, or into delayed nausea and vomiting which appears after 24 hours from chemotherapy administration up to 120 hours. In Japan, only limited efficacy for delayed nausea and vomiting has been shown with currently available agents.

With a single administration before chemotherapy (cisplatin, etc), Aloxi showed to be effective not only in acute nausea and vomiting, but also in delayed nausea and vomiting, in which currently available agents were not able to show adequate efficacy. Aloxi has a prolonged plasma half-life of approximately 40 hours, and possesses high binding affinity and selectivity towards the 5-HT3 receptors. Furthermore, use of Aloxi is recommended for the prevention of chemotherapy induced nausea and vomiting following Moderately Emetogenic Chemotherapy (non AC/EC) in the 2009 International Antiemetic Guideline of the European Society for Medical Oncology (ESMO)/ Multinational Association of Supportive Care in Cancer (MASCC).

Aloxi is approved in 63 countries worldwide, reaching global sales of more than400M USD(approx.36B yen) last year.

https://www.bionity.com/en/news/116773/the-5-ht3-receptor-antagonist-aloxi-launched-in-japan.html